Irmgard Irminger-Finger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Irmgard Irminger-Finger has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Anis Feki
Department of Obstetrics and Gynecology, HFR Fribourg—Hôpital cantonal , Fribourg
3 shared publications Charles Edward Jefford
Department of Geriatrics and Department of Gynecology and Obstetrics, Biology of Aging Laboratory, Geneva University and University Hospitals, Geneva, Switzerland
3 shared publicationsKarl-Heinz Krause
Biology of Aging Laboratory, Department of Geriatrics, University of Geneva, Chemin de Petit Bel Air 2, CH-1225 Geneva/Chêne-Bourg, Switzerland
2 shared publicationsLaetitia Cartier
Biology of Aging Laboratory, Department of Geriatrics, University of Geneva, Chemin de Petit Bel Air 2, CH-1225 Geneva/Chêne-Bourg, Switzerland
2 shared publicationsAndrea Bianco
Department of Cardiothoracic and Respiratory Science–SUN, Naples, Italy
1 shared publicationAnna Liossi
Department of Cytopathology, Laikon Peripheral General University Hospital, Athens, Greece
1 shared publication
Latest Publications
- 20 June 2017
- Published by Springer Nature
- p. 428-432
BARD1
- 1 September 2014
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 54, 356-367
Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs
- 1 September 2014
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 54, 356-367
Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs
- 1 January 2014
- Published by Springer Nature
- p. 1-5
BARD1
- 1 January 2011
- Published by Springer Nature
- p. 339-342
BARD1
- Open Access
- 1 January 2008
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 1 (1) , 20
Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity
Malignant melanomas are characterized by increased karyotypic complexity, extended aneuploidy and heteroploidy. We report a melanoma metastasis to the peritoneal cavity with an exceptionally stable, abnormal pseudodiploid karyotype as verified by G-Banding, subtelomeric, centromeric and quantitative Fluorescence in Situ Hybridization (FISH). Interestingly this tumor had no detectable telomerase activity as indicated by the Telomere Repeat Amplification Protocol. Telomeric Flow-FISH and quantitative telomeric FISH on mitotic preparations showed that malignant cells had relatively short telomeres. Microsatellite instability was ruled out by the allelic pattern of two major mononucleotide repeats. Our data suggest that a combination of melanoma specific genomic imbalances were sufficient and enough for this fatal tumor progression, that was not accompanied by genomic instability, telomerase activity, or the engagement of the alternative recombinatorial telomere lengthening pathway.
- 1 January 2008
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 1 (1) , 20
Open AccessUnusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity
Malignant melanomas are characterized by increased karyotypic complexity, extended aneuploidy and heteroploidy. We report a melanoma metastasis to the peritoneal cavity with an exceptionally stable, abnormal pseudodiploid karyotype as verified by G-Banding, subtelomeric, centromeric and quantitative Fluorescence in Situ Hybridization (FISH). Interestingly this tumor had no detectable telomerase activity as indicated by the Telomere Repeat Amplification Protocol. Telomeric Flow-FISH and quantitative telomeric FISH on mitotic preparations showed that malignant cells had relatively short telomeres. Microsatellite instability was ruled out by the allelic pattern of two major mononucleotide repeats. Our data suggest that a combination of melanoma specific genomic imbalances were sufficient and enough for this fatal tumor progression, that was not accompanied by genomic instability, telomerase activity, or the engagement of the alternative recombinatorial telomere lengthening pathway.
- 1 January 2008
- Published by Springer Nature
- p. 293-301
A Role of BRCA1-Associated Protein BARD1 in Oxidative Stress Response and Signaling and Proliferation Control
- 1 January 2008
- Published by Springer Nature
- p. 293-301
A Role of BRCA1-Associated Protein BARD1 in Oxidative Stress Response and Signaling and Proliferation Control
- 1 July 2007
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 39 (7-8) , 1278-1279
Cancer therapy: New drugs are emerging based on molecular targeting but still many challenges
- 1 July 2007
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 39 (7-8) , 1278-1279
Cancer therapy: New drugs are emerging based on molecular targeting but still many challenges
- 10 May 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (14) , 1844-1851
Science of Cancer and Aging
This review provides an overview of a selection of the most pertinent molecular pathways that link cancer and aging and focuses on those where recent advances were most important. When organizing the bulk of information on this subject, I became aware of the fact that the most evident partition, namely, mechanisms that influence aging and mechanisms that influence cancer occurrence, is difficult to apply. Most mechanisms explaining the aging process are also those that influence carcinogenesis. Mechanisms that are described in tumor suppressor pathways are also contributors to the aging process. From an intuitive point of view, there are phenomena that have traditionally been contributed to aging others to cancer-inducing factors and they are presented herein.
- 10 May 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (14) , 1844-1851
Science of Cancer and Aging
This review provides an overview of a selection of the most pertinent molecular pathways that link cancer and aging and focuses on those where recent advances were most important. When organizing the bulk of information on this subject, I became aware of the fact that the most evident partition, namely, mechanisms that influence aging and mechanisms that influence cancer occurrence, is difficult to apply. Most mechanisms explaining the aging process are also those that influence carcinogenesis. Mechanisms that are described in tumor suppressor pathways are also contributors to the aging process. From an intuitive point of view, there are phenomena that have traditionally been contributed to aging others to cancer-inducing factors and they are presented herein.
- 1 May 2006
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (5) , 382-391
Is there more to BARD1 than BRCA1?
BRCA1-associated ring domain 1 (BARD1) is the main binding partner of BRCA1 and is essential for the tumour-suppressor functions of BRCA1. The BARD1–BRCA1 heterodimer has ubiquitin ligase activity that targets proteins involved in cell-cycle regulation and DNA repair for degradation. BARD1 has a BRCA1-independent function in mediating p53-dependent apoptosis. It binds to p53, facilitating its phosphorylation and stabilization. BARD1 is expressed in most proliferative tissues, including that of the breast, ovary and uterus. It is transcriptionally upregulated in response to DNA damage, hypoxia and hormone signalling. Its translation is activated by cell-cycle-dependent phosphorylation. BARD1 is mutated or truncated in breast, ovarian and uterine tumour samples. Depletion of BARD1 leads to early embryonic lethality in mice, and genomic instability in vitro and in vivo; phenotypes that are also observed for BRCA1 or BRCA2 deficiencies.
- 1 May 2006
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (5) , 382-391
Is there more to BARD1 than BRCA1?
BRCA1-associated ring domain 1 (BARD1) is the main binding partner of BRCA1 and is essential for the tumour-suppressor functions of BRCA1. The BARD1–BRCA1 heterodimer has ubiquitin ligase activity that targets proteins involved in cell-cycle regulation and DNA repair for degradation. BARD1 has a BRCA1-independent function in mediating p53-dependent apoptosis. It binds to p53, facilitating its phosphorylation and stabilization. BARD1 is expressed in most proliferative tissues, including that of the breast, ovary and uterus. It is transcriptionally upregulated in response to DNA damage, hypoxia and hormone signalling. Its translation is activated by cell-cycle-dependent phosphorylation. BARD1 is mutated or truncated in breast, ovarian and uterine tumour samples. Depletion of BARD1 leads to early embryonic lethality in mice, and genomic instability in vitro and in vivo; phenotypes that are also observed for BRCA1 or BRCA2 deficiencies.
- Open Access
- 20 December 2005
- Published by Wiley in International Journal of Cancer
- Vol. 118 (5) , 1215-1226
Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
Mutations in tumor‐suppressor gene BARD1 have been found in inherited and spontaneous breast, ovarian and uterine cancers. BARD1 plays a critical role in DNA repair and ubiquitination as binding partner of BRCA1, with which it colocalizes to nuclear dots. Independently of BRCA1, BARD1 can induce p53‐dependent apoptosis in response to genotoxic stress. Therefore, BARD1 or p53 might be defective in cancer cells spared from apoptosis. We investigated BARD1 and p53 expression in ovarian, breast and non‐small‐cell lung cancers. BARD1 expression was highly upregulated and cytoplasmic in most cancer cells, while weak nuclear staining was observed in the surrounding normal tissue. Maximal BARD1 expression was associated with the most malignant ovarian cancer, clear cell carcinoma. In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease‐free survival. In contrast to breast and ovarian cancers, no correlation of BARD1 expression with either grade or stage could be determined for lung cancer. RT‐PCR, performed on 10 ovarian cancers, revealed absence of the 5′ portion of the BARD1 transcript in 7 tumors, and sequencing of the remaining 3 identified a missense mutation (A1291G) resulting in an amino acid change of glutamine 406 to arginine. These data suggest that genetic and epigenetic changes might lead to elevated cytoplasmic expression of BARD1 and that cytoplasmic BARD1 might be a poor prognostic factor for breast and ovarian cancers.
- 20 December 2005
- Published by Wiley in International Journal of Cancer
- Vol. 118 (5) , 1215-1226
Open AccessAberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
Mutations in tumor‐suppressor gene BARD1 have been found in inherited and spontaneous breast, ovarian and uterine cancers. BARD1 plays a critical role in DNA repair and ubiquitination as binding partner of BRCA1, with which it colocalizes to nuclear dots. Independently of BRCA1, BARD1 can induce p53‐dependent apoptosis in response to genotoxic stress. Therefore, BARD1 or p53 might be defective in cancer cells spared from apoptosis. We investigated BARD1 and p53 expression in ovarian, breast and non‐small‐cell lung cancers. BARD1 expression was highly upregulated and cytoplasmic in most cancer cells, while weak nuclear staining was observed in the surrounding normal tissue. Maximal BARD1 expression was associated with the most malignant ovarian cancer, clear cell carcinoma. In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease‐free survival. In contrast to breast and ovarian cancers, no correlation of BARD1 expression with either grade or stage could be determined for lung cancer. RT‐PCR, performed on 10 ovarian cancers, revealed absence of the 5′ portion of the BARD1 transcript in 7 tumors, and sequencing of the remaining 3 identified a missense mutation (A1291G) resulting in an amino acid change of glutamine 406 to arginine. These data suggest that genetic and epigenetic changes might lead to elevated cytoplasmic expression of BARD1 and that cytoplasmic BARD1 might be a poor prognostic factor for breast and ovarian cancers.